Incyte Corporation Incyte Corporation

Incyte Corporation

INCY

Rankning i aktier #999
Incyte Corporation is a biopharmaceutical firm engaged in the research,... Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.
Aktiekurs
$116.38
Senast synkroniserad: 2026-10-20
Marknadsvärde
$23.59B
Förändring (1 dag)
2.76%
Förändring (1 år)
33.31%
Land
US
Handel Incyte Corporation (INCY)

Kategori

Healthcare
Historik för aktiesplit för Incyte Corporation (INCY)
Aktien Incyte Corporation (symbol: INCY) har genomgått totalt 2 aktiesplitar.
Den senaste spliten skedde den Sep 01, 2000.
En INCY-aktie köpt före Nov 10, 1997 motsvarar nu 4 INCY-aktier.
Lista över aktiesplitar
År Split Multipel Kumulativ multipel
2000-09-01 2:1 x2 x4
1997-11-10 2:1 x2 x2
Aktiesplitar för liknande företag eller konkurrenter
Företag Antal aktiesplitar Kumulativ multipel Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 1 x2
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 0 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 1 x3
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 0 -
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
 0 -
NL